MHRA-100364-PIP01-21

Key Facts

Active Substance
Active Substance:
  • Respiratory Syncytial Virus (RSV) PreF3 recombinant Fusion protein/AS01
Invented Name
Not available at present
PIP Number MHRA-100364-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • powder and suspension for suspension for injection
Therapeutic area
Therapeutic area:
  • Vaccines
Conditions / Indications
Conditions / Indications:
  • Prevention of lower respiratory tract disease caused by respiratory syncytial virus
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Respiratory Syncytial Virus (RSV) PreF3 recombinant Fusion protein/AS01.pdf
Published Date 29/07/2022